类风湿关节炎药物治疗疗效的系统文献研究:为2019年EULAR管理建议更新提供依据
该研究通过系统文献检索评估了各类改善病情抗风湿药(DMARD)及糖皮质激素在类风湿关节炎(RA)患者中的疗效,共纳入136篇文献。结果显示多种生物制剂和靶向合成DMARD有效,TNFi治疗失败后换用其他TNFi或非TNFi生物制剂有效,生物类似药非劣于原研药,长期严格缓解患者可减量但残留活动者减量有复发风险。
要点
- 多种bDMARD和tsDMARD对RA显示疗效
- TNFi失败后换用其他TNFi或非TNFi bDMARD有效
- 长期严格缓解者可减量,残留活动者减量复发风险增加
核心结论
- 该SLR为EULAR RA管理建议更新提供了多种治疗方案证据基础。
研究设计与样本
- 系统文献研究,检索MEDLINE、Embase和Cochrane Library 2016年至2019年3月8日发表的文献。
- 筛选234篇摘要详细评估,最终纳入136篇。
主要发现
- 多种bDMARD和tsDMARD的疗效得到证实。
- TNFi治疗失败后换用另一种TNFi或非TNFi bDMARD有效。
- 长期严格临床缓解患者可减量DMARD,但有残留疾病活动(包括LDA)者减量期间复发风险增加。
- 生物类似药非劣于其原研药。
临床怎么用
- TNFi治疗失败后可考虑换用另一种TNFi或非TNFi bDMARD。
- 对长期严格临床缓解患者可考虑DMARD减量,但残留活动者减量需警惕复发。
- 生物类似药可作为原研药的替代选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To inform the 2019 update of the European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA). METHODS: A systematic literature research (SLR) to investigate the efficacy of any disease-modifying antirheumatic drug (DMARD) (conventional synthetic (cs)DMARD, biological (b) and biosimilar DMARD, targeted synthetic (ts)DMARD) or glucocorticoid (GC) therapy in patients with RA was done by searching MEDLINE, Embase and the Cochrane Library for articles published between 2016 and 8 March 2019. RESULTS: 234 abstracts were selected for detailed assessment, with 136 finally included. They comprised the efficacy of bDMARDs versus placebo or other bDMARDs, efficacy of Janus kinase (JAK) inhibitors (JAKi) across different patient populations and head-to-head of different bDMARDs versus JAKi or other bDMARDs. Switching of bDMARDs to other bDMARDs or tsDMARDs, strategic trials and tapering studies of bDMARDs, csDMARDs and JAKi were assessed. The drugs evaluated included abatacept, adalimumab, ABT-122, baricitinib, certolizumab pegol, SBI-087, CNTO6785, decernotinib, etanercept, filgotinib, golimumab, GCs, GS-9876, guselkumab, hydroxychloroquine, infliximab, leflunomide, mavrilimumab, methotrexate, olokizumab, otilimab, peficitinib, rituximab, sarilumab, salazopyrine, secukinumab, sirukumab, tacrolimus, tocilizumab, tofacitinib, tregalizumab, upadacitinib, ustekinumab and vobarilizumab. The efficacy of many bDMARDs and tsDMARDs was shown. Switching to another tumour necrosis factor inhibitor (TNFi) or non-TNFi bDMARDs after TNFi treatment failure is efficacious. Tapering of DMARDs is possible in patients achieving long-standing stringent clinical remission; in patients with residual disease activity (including patients in LDA) the risk of flares is increased during the tapering. Biosimilars are non-inferior to their reference products. CONCLUSION: This SLR informed the task force regarding the evidence base of various therapeutic regimen for the development of the update of EULAR's RA management recommendation.
引用
- Kerschbaumer A, Sepriano A, Smolen JS, et al. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2020. PMID: 32033937. doi:10.1136/annrheumdis-2019-216656
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。